All data are based on the daily closing price as of June 27, 2025
e
Eisai
4523.TSE
28.24 USD
0.28
+1.00%
Overview
Last close
28.24 usd
Market cap
7.97B usd
52 week high
46.51 usd
52 week low
24.09 usd
Target price
30.95 usd
Valuation
P/E
25.0031
Forward P/E
32.6797
Price/Sales
1.4645
Price/Book Value
1.3502
Enterprise Value
7.32B usd
EV/Revenue
1.3397
EV/EBITDA
10.1211
Key financials
Revenue TTM
5.47B usd
Gross Profit TTM
4.30B usd
EBITDA TTM
602.38M usd
Earnings per Share
1.14 usd
Dividend
1.11 usd
Total assets
9.30B usd
Net debt
-523.43M usd
About
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate; and a clinical trial collaboration and supply agreement with Medivir for the evaluation of fostrox, a liver-targeted treatment. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.